This website is designed to provide information about the ICON8 Trials Programme encompassing ICON8 and ICON8B for both patients and collaborators.
ICON8 is a randomised three-arm, three stage Gynaecologic Cancer InterGroup (GCIG) phase III trial designed to evaluate the safety and efficacy of dose-dense, dose-fractionated carboplatin-paclitaxel chemotherapy in the treatment of patients with ovarian cancer.
Learn more about ICON8:
ICON8B is a randomised 3-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.
Learn more about ICON8B:
The latest accrual figures for February 2018 have been released.
The total numbers recruited:
across all the regions.